Factor XI antisense oligonucleotide for prevention of venous thrombosis.
about
Factor XI and contact activation as targets for antithrombotic therapyIntegrated Safety Assessment of 2'-O-Methoxyethyl Chimeric Antisense Oligonucleotides in NonHuman Primates and Healthy Human VolunteersThe Effects of 2'-O-Methoxyethyl Containing Antisense Oligonucleotides on Platelets in Human Clinical Trials.Selection and characterization of a DNA aptamer inhibiting coagulation factor XIa.Collateral Lethality: A new therapeutic strategy in oncologyAllosteric inhibition of factor XIa. Sulfated non-saccharide glycosaminoglycan mimetics as promising anticoagulants.Differential Kinetics of Coagulation Factors and Natural Anticoagulants in Patients with Liver Cirrhosis: Potential Clinical ImplicationsThe polyphosphate-factor XII pathway drives coagulation in prostate cancer-associated thrombosis.FXIa and platelet polyphosphate as therapeutic targets during human blood clotting on collagen/tissue factor surfaces under flowFactor XIa and Thrombin Generation Are Elevated in Patients with Acute Coronary Syndrome and Predict Recurrent Cardiovascular EventsGenetic diminution of circulating prothrombin ameliorates multiorgan pathologies in sickle cell disease micePlatelet-Derived Short-Chain Polyphosphates Enhance the Inactivation of Tissue Factor Pathway Inhibitor by Activated Coagulation Factor XI.Identification and characterization of modified antisense oligonucleotides targeting DMPK in mice and nonhuman primates for the treatment of myotonic dystrophy type 1.Prospective study of circulating factor XI and incident venous thromboembolism: The Longitudinal Investigation of Thromboembolism Etiology (LITE).Lack of association of plasma factor XI with incident stroke and coronary heart disease: The Atherosclerosis Risk in Communities (ARIC) StudyLong noncoding RNAs in cancer: from function to translation.Suppressing angiotensinogen synthesis attenuates kidney cyst formation in a Pkd1 mouse model.Directed Alternative Splicing in Nijmegen Breakage Syndrome: Proof of Principle Concerning Its Therapeutical ApplicationAntisense inhibition of apolipoprotein (a) to lower plasma lipoprotein (a) levels in humansCoagulation Factor XI Promotes Distal Platelet Activation and Single Platelet Consumption in the Bloodstream Under Shear Flow.Factor XI Deficiency Protects Against Atherogenesis in Apolipoprotein E/Factor XI Double Knockout Mice.A comparison of the effects of factor XII deficiency and prekallikrein deficiency on thrombus formation.Stabilin-1 and Stabilin-2 are specific receptors for the cellular internalization of phosphorothioate-modified antisense oligonucleotides (ASOs) in the liver.How it all starts: Initiation of the clotting cascade.Long Noncoding RNAs in Cancer PathwaysFactor XI as a Therapeutic Target.Factor XIa inhibitors: A review of the patent literature.Why factor XI deficiency is a clinical concern.The delivery of therapeutic oligonucleotidesAZD9150, a next-generation antisense oligonucleotide inhibitor of STAT3 with early evidence of clinical activity in lymphoma and lung cancer.Factors XI and XII as Targets for New Anticoagulants.Antisense Oligonucleotides: Treatment Strategies and Cellular Internalization.Anticoagulation therapy in 2015: where we are and where we are going.Acute and persistent platelet and coagulant activities in atherothrombosis.Medical device-induced thrombosis: what causes it and how can we prevent it?Factor XII: a novel target for safe prevention of thrombosis and inflammation.New products for the treatment of haemophilia.Prothrombotic aspects of sickle cell disease.Epigenetics and allergy: from basic mechanisms to clinical applications.Injection site reactions after subcutaneous oligonucleotide therapy
P2860
Q27024190-37ABB3E1-5BF1-490E-ADFF-EB99F4E95A4AQ28821280-B73D5D82-4635-4216-909F-AA1ED483FD64Q33438876-D82DE8F7-0518-4679-972E-59CA4984849AQ33704680-3FBAB076-A389-4A55-8BC5-67F892FFFAABQ34513800-AF2B8E23-6B48-44EF-A149-ABD1E2556CD3Q35920828-847ED015-CEAF-4052-9C32-A8F297F9AD85Q36015509-2D21177E-852A-4D9F-8A7A-261669C4CAADQ36051099-E4081FC5-6DA3-45EA-A48E-17E6E3D91A98Q36070475-BBEE4366-9FEF-40E4-9682-1FB0DCD760A5Q36078435-023BBD86-C6A9-40D4-A6CF-3311FFFAC583Q36143261-FFA44473-6D07-497F-84F7-20EEAD6FA118Q36169665-8102658F-A9E2-4904-8EE9-7231265246E0Q36186164-C029FEB5-9AD5-4F34-B3A8-57DB23A19CFEQ36199721-C6694245-1BF6-4486-A216-321FB9DD3036Q36206122-9334064B-437A-4675-B873-060DD4837D24Q36353705-E7E772E5-912B-4BAC-9D61-7C6CC63E709BQ36385359-4A7F0946-8CC5-4D1D-9340-51B93767C65BQ36582790-7A52B11B-9BB2-4782-86B2-902E51AAC333Q36617508-053B014D-48B6-489A-8002-F990A7316779Q36619746-9BAD7E6C-67D5-45C1-9A5D-F2CD133FC961Q36672353-77E56223-8D23-4032-B263-4DD753698493Q36767718-CD106AE8-BA35-46D2-B560-8CC444A4A6FDQ36775577-1CBFD988-2004-4BF2-841F-7A18692BEA2CQ36783613-A90AA959-576A-4A2F-9135-F280A7B435A4Q36796798-4A54C213-8899-4C15-98A4-33B9978F91EEQ37033749-1ADA8683-1B59-4D75-AEC5-218E5431FD6FQ37087491-36E1F2AF-DF29-4066-A2F0-78EEAE72FD9DQ37108888-1A630FB8-0FB9-4C27-BC3E-2AD3553F2F68Q37210936-5C4AB157-1E04-4BEA-859C-52B240A009E2Q37613445-846B8465-7C17-4597-A387-3B53E6DBEA05Q37662547-B1D5B3D6-5E25-485F-9456-75C88547E715Q37733136-F8250B9F-C6E9-4D9E-85B8-99B4F1D9A2D8Q38362373-5332AE2A-C1A0-43FE-A9F0-D6C245290F29Q38543304-EB17816B-5B68-4F0B-8B35-76C2E8C64768Q38543320-A73E63B8-F3B4-42B9-9F2D-F910DBFDC17AQ38587540-8C3A7E52-1826-491A-BD7B-309EF63FBF52Q38604626-FBBFFE4E-C575-4763-98C5-59B23E0B1F51Q38696998-CD5B8CCD-130A-4934-B202-A7D4A5025C05Q38742430-C4933A3D-2CC7-41E4-97F3-FBF59CECD996Q38803235-B24740FE-6098-412C-B062-8C8DC355DDF3
P2860
Factor XI antisense oligonucleotide for prevention of venous thrombosis.
description
2014 nî lūn-bûn
@nan
2014 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Factor XI antisense oligonucleotide for prevention of venous thrombosis.
@ast
Factor XI antisense oligonucleotide for prevention of venous thrombosis.
@en
type
label
Factor XI antisense oligonucleotide for prevention of venous thrombosis.
@ast
Factor XI antisense oligonucleotide for prevention of venous thrombosis.
@en
prefLabel
Factor XI antisense oligonucleotide for prevention of venous thrombosis.
@ast
Factor XI antisense oligonucleotide for prevention of venous thrombosis.
@en
P2093
P2860
P356
P1476
Factor XI antisense oligonucleotide for prevention of venous thrombosis.
@en
P2093
Annelise Segers
Brett P Monia
Claudette Bethune
David Gailani
FXI-ASO TKA Investigators
Gary E Raskob
Harry R Büller
Jeffrey I Weitz
Peter Verhamme
Sanjay Bhanot
P2860
P304
P356
10.1056/NEJMOA1405760
P407
P577
2014-12-07T00:00:00Z